Tenax Therapeutics, Inc.
Quick facts
Phase 3 pipeline
- TNX-103 · Cardiovascular
TNX-103 is a cardiac myosin inhibitor that reduces the force of heart muscle contraction to improve cardiac function in heart failure patients.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Tenax Therapeutics, Inc.
What is Tenax Therapeutics, Inc.'s pipeline?
Tenax Therapeutics, Inc. has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include TNX-103.
Related
- Sector hub: All tracked pharma companies